Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pathogenesis and treatment of renal failure in multiple myeloma

Leukemia volume 22, pages 1485–1493 (2008)Cite this article

Abstract

Renal failure is a frequent complication in patients with multiple myeloma (MM) that causes significant morbidity. In the majority of cases, renal impairment is caused by the accumulation and precipitation of light chains, which form casts in the distal tubules, resulting in renal obstruction. In addition, myeloma light chains are also directly toxic on proximal renal tubules, further adding to renal dysfunction. Adequate hydration, correction of hypercalcemia and hyperuricemia and antimyeloma therapy should be initiated promptly. Recovery of renal function has been reported in a significant proportion of patients treated with conventional chemotherapy, especially when high-dose dexamethasone is also used. Severe renal impairment and large amount of proteinuria are associated with a lower probability of renal recovery. Novel agents, such as thalidomide, bortezomib and lenalidomide, have significant activity in pretreated and untreated MM patients. Although there is limited experience with thalidomide and lenalidomide in patients with renal failure, data suggest that bortezomib may be beneficial in this population. Clinical studies that have included newly diagnosed and refractory patients indicate that bortezomib-based regimens may result in rapid reversal of renal failure in up to 50% of patients and that full doses of bortezomib can be administered without additional toxicity.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693–1695.

    Article  CAS  PubMed  Google Scholar 

  2. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.

    Article  CAS  PubMed  Google Scholar 

  3. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.

    Article  PubMed  Google Scholar 

  4. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007; 48: 337–341.

    Article  CAS  PubMed  Google Scholar 

  5. Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.

    Article  CAS  PubMed  Google Scholar 

  6. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.

    Article  CAS  PubMed  Google Scholar 

  7. Batuman V, Dreisbach AW, Cyran J . Light-chain binding sites on renal brush-border membranes. Am J Physiol 1990; 258: F1259–F1265.

    CAS  PubMed  Google Scholar 

  8. Batuman V, Guan S . Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells. Am J Physiol 1997; 272: F521–F530.

    CAS  PubMed  Google Scholar 

  9. Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Campbell WC et al. Myeloma light chains are ligands for cubilin (gp280). Am J Physiol 1998; 275: F246–F254.

    CAS  PubMed  Google Scholar 

  10. Santostefano M, Zanchelli F, Zaccaria A, Poletti G, Fusaroli M . The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol 2005; 18: 659–675.

    CAS  PubMed  Google Scholar 

  11. Huang ZQ, Sanders PW . Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 1995; 73: 810–817.

    CAS  PubMed  Google Scholar 

  12. Huang ZQ, Sanders PW . Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 1997; 99: 732–736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ying WZ, Sanders PW . Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001; 158: 1859–1866.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sanders PW, Booker BB, Bishop JB, Cheung HC . Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 1990; 85: 570–576.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pirani CL, Valeri A, D'Agati V, Appel GB . Renal toxicity of nonsteroidal anti-inflammatory drugs. Contrib Nephrol 1987; 55: 159–175.

    Article  CAS  PubMed  Google Scholar 

  16. Sanders PW, Booker BB . Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89: 630–639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Blade J, Rosinol L . Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 635–652.

    Article  CAS  PubMed  Google Scholar 

  18. Solomon A, Weiss DT, Kattine AA . Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324: 1845–1851.

    Article  CAS  PubMed  Google Scholar 

  19. Batuman V . Proximal tubular injury in myeloma. Contrib Nephrol 2007; 153: 87–104.

    Article  CAS  PubMed  Google Scholar 

  20. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA . The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001; 98: 714–720.

    Article  CAS  PubMed  Google Scholar 

  21. Ronco P, Plaisier E, Mougenot B, Aucouturier P . Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 2006; 1: 1342–1350.

    Article  CAS  PubMed  Google Scholar 

  22. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004; 104: 40–42.

    Article  CAS  PubMed  Google Scholar 

  23. Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V . Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 2002; 62: 1977–1988.

    Article  CAS  PubMed  Google Scholar 

  24. Sengul S, Zwizinski C, Batuman V . Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 2003; 284: F1245–F1254.

    Article  CAS  PubMed  Google Scholar 

  25. Keeling J, Herrera GA . The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol 2007; 153: 116–134.

    Article  CAS  PubMed  Google Scholar 

  26. Sanders PW, Herrera GA, Galla JH . Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int 1987; 32: 851–861.

    Article  CAS  PubMed  Google Scholar 

  27. Guan S, el-Dahr S, Dipp S, Batuman V . Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J Investig Med 1999; 47: 496–501.

    CAS  PubMed  Google Scholar 

  28. DeFronzo RA, Cooke CR, Wright JR, Humphrey RL . Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978; 57: 151–166.

    Article  CAS  Google Scholar 

  29. Merlini G, Bellotti V . Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583–596.

    Article  CAS  PubMed  Google Scholar 

  30. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G . Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11–22.

    Article  CAS  PubMed  Google Scholar 

  31. Buxbaum J, Gallo G . Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am 1999; 13: 1235–1248.

    Article  CAS  PubMed  Google Scholar 

  32. Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42: 1154–1163.

    Article  PubMed  Google Scholar 

  33. Blade J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcala A et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001; 2: 272–278.

    Article  CAS  PubMed  Google Scholar 

  34. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520..

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J . Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. QJ Med 1991; 79: 517–525.

    CAS  Google Scholar 

  36. Abbott KC, Agodoa LY . Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001; 56: 207–210.

    CAS  PubMed  Google Scholar 

  37. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219–9226.

    Article  PubMed  Google Scholar 

  38. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546–549.

    Article  CAS  PubMed  Google Scholar 

  39. Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Pouli A, Christoulas D et al. Cystatin-C is a sensitive marker of renal impairment with an independent predictive value for survival in multiple myeloma; reduction post bortezomib monotherapy. Blood 2007; 110 (Abstract #1484).

  40. Mayo MM, Johns GS . Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol 2007; 153: 44–65.

    Article  CAS  PubMed  Google Scholar 

  41. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281–289.

    Article  CAS  PubMed  Google Scholar 

  42. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379–398.

    Article  PubMed  Google Scholar 

  43. Pozzi C, Pasquali S, Donini U, Casanova S, Banfi G, Tiraboschi G et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italien Renal Immunopathology Group. Clin Nephrol 1987; 28: 1–9.

    CAS  PubMed  Google Scholar 

  44. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G . Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988; 33: 1175–1180.

    Article  CAS  PubMed  Google Scholar 

  45. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE . Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990; 150: 863–869.

    Article  CAS  PubMed  Google Scholar 

  46. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143: 777–784.

    Article  PubMed  Google Scholar 

  47. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007; 18: 886–895.

    Article  CAS  PubMed  Google Scholar 

  48. Hutchison CA, Cook M, Basu S, Cockwell P, Basnayake K, Bradwell A . Combined chemotherapy and high cut-off hemodialysis improve outcomes in multiple myeloma patients with severe renal failure. Blood 2007; 110 (Abstract #3610).

  49. Misiani R, Tiraboschi G, Mingardi G, Mecca G . Management of myeloma kidney: an anti-light-chain approach. Am J Kidney Dis 1987; 10: 28–33.

    Article  CAS  PubMed  Google Scholar 

  50. Korzets A, Tam F, Russell G, Feehally J, Walls J . The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis 1990; 16: 216–223.

    Article  CAS  PubMed  Google Scholar 

  51. Iggo N, Palmer AB, Severn A, Trafford JA, Mufti GJ, Taube D et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989; 73: 903–910.

    CAS  PubMed  Google Scholar 

  52. Johnson WJ, Kyle RA, Dahlberg PJ . Dialysis in the treatment of multiple myeloma. Mayo Clin Proc 1980; 55: 65–72.

    CAS  PubMed  Google Scholar 

  53. Shetty A, Oreopoulos DG . Continuous ambulatory peritoneal dialysis in end-stage renal disease due to multiple myeloma. Perit Dial Int 1995; 15: 236–240.

    CAS  PubMed  Google Scholar 

  54. Boccadoro M, Pileri A . Standard chemotherapy for myelomatosis: an area of great controversy. Hematol Oncol Clin North Am 1992; 6: 371–382.

    Article  CAS  PubMed  Google Scholar 

  55. Eriksson T, Hoglund P, Turesson I, Waage A, Don BR, Vu J et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 2003; 55: 1701–1706.

    Article  CAS  PubMed  Google Scholar 

  56. Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004; 73: 98–103.

    Article  CAS  PubMed  Google Scholar 

  57. Pineda-Roman M, Tricot G . High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 2007; 153: 182–194.

    Article  CAS  PubMed  Google Scholar 

  58. Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL . Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003; 122: 160–161.

    Article  CAS  PubMed  Google Scholar 

  59. Montagut C, Bosch F, Villela L, Rosinol L, Blade J . Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymphoma 2004; 45: 1711–1712.

    Article  CAS  PubMed  Google Scholar 

  60. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560.

    Article  CAS  PubMed  Google Scholar 

  61. Rosinol L, Oriol A, Mateos MV, Sureda A, Garcia-Sanchez P, Gutierrez N et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25: 4452–4458.

    Article  CAS  PubMed  Google Scholar 

  62. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498–1505.

    CAS  PubMed  Google Scholar 

  63. Mulkerin D, Remick S, Takimoto C, Ivy P, Karol M, Eton O . Safety, Tolerability, and Pharmacology of Bortezomib in Cancer Patients with Renal Failure Requiring Dialysis: Results from a Prospective Phase 1 Study. Blood 2007; 110 (Abstract #3477).

  64. Mulkerin D, Remick S, Ramanathan R, Hamilton A, Takimoto C, Davies A et al. A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function. J Clin Oncol 2006; 24 (Abstract #2032).

  65. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005; 103: 1195–1200.

    Article  CAS  PubMed  Google Scholar 

  66. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008; 22: 842–849.

    Article  CAS  PubMed  Google Scholar 

  67. Ailawadhi S, Mashtare TL, Coignet MV, Depaolo DM, Miller KC, Wilding G et al. Renal dysfunction does not affect clinical response in multiple Myeloma (MM) patients treated with Bortezomib-based regimens. Blood 2007; 110 (Abstract #1477).

  68. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604–2606.

    Article  CAS  PubMed  Google Scholar 

  69. Ludwig H, Drach J, Graf H, Lang A, Meran JG . Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411–1414.

    Article  CAS  PubMed  Google Scholar 

  70. Ludwig H, Adam Z, Hajek R, Greil R, Keil F, Zojer N et al. Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study. Blood 2007; 110 (Abstract #3603).

  71. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukemia and Lymphoma 2008; 49: 890–895.

    Article  CAS  PubMed  Google Scholar 

  72. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. Blood 2007; 110 (Abstract #74).

  73. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 2007; 25: 4459–4465.

    Article  CAS  PubMed  Google Scholar 

  74. Kastritis E, Dimopoulos MA . The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 2007; 8: 497–509.

    Article  CAS  PubMed  Google Scholar 

  75. Weber D, Wang M, Chen C, Belch A, Stadtmauer EA, Niesvisky R et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 Phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood 2006; 108 (Abstract #3547).

  76. Reece DE, Masih-Khan E, Chen C, Wang L, Dean S, Kukreti V et al. Use of lenalidomide (Revlimid(R) +/− corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels. Blood 2006; 108 (Abstract #3548).

  77. Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007; 138: 640–643.

    Article  CAS  PubMed  Google Scholar 

  78. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008; 111: 1101–1109.

    Article  CAS  PubMed  Google Scholar 

  79. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007; 47: 1466–1475.

    Article  CAS  PubMed  Google Scholar 

  80. Carlson K . Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005; 35: 985–990.

    Article  CAS  PubMed  Google Scholar 

  81. Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947–952.

    CAS  PubMed  Google Scholar 

  82. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, Alegre A, Blade J, Martinez R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000; 1: 28–36.

    Article  CAS  PubMed  Google Scholar 

  83. Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33.

    Article  PubMed  Google Scholar 

  84. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    Article  CAS  PubMed  Google Scholar 

  85. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  86. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 605–611.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

    M A Dimopoulos & E Kastritis

  2. Hematology Department, Institut Clinic de Malaties Hematologiques i Oncologiques, Hospital Clínic, Postgraduate School of Hematology Farreras Valentí, Universitat de Barcelona, Barcelona, Spain

    L Rosinol & J Bladé

  3. Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Vienna, Austria

    H Ludwig

Authors
  1. M A Dimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Kastritis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Rosinol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Bladé
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Dimopoulos.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dimopoulos, M., Kastritis, E., Rosinol, L. et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22, 1485–1493 (2008). https://doi.org/10.1038/leu.2008.131

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.131

Keywords

  • multiple myeloma
  • renal failure
  • light chains
  • renal recovery
  • bortezomib
  • thalidomide
  • lenalidomide

This article is cited by

Search

Advanced search

Quick links